文献速递乳腺癌放疗放疗物理与技术

KROG 08-06 Ⅲ期试验个体化病例审查:乳腺癌内乳淋巴结照射的协议依从性

Individual case review in a phase 3 randomized trial to investigate the role of internal mammary lymph node irradiation for breast cancer: Korean Radiation Oncology Group 08-06 study.
PubMed 文献 · Radiother Oncol · 2017-02-21

该研究对KROG-0806Ⅲ期随机试验中747例受试者按内乳淋巴结照射、肿瘤侧别和手术方式分为8个亚组,每组随机抽取15%共102例进行个体化病例审查,评估放疗计划与协议的一致性。结果显示放疗计划总体依从性可接受,但不同亚组和照射野安排间存在显著差异,基于内乳淋巴结剂量的估计生存获益在全组、保乳手术组和乳房切除组分别为7.7%、8.4%和7.2%。

要点

  • KROG-0806试验中随机抽取102例进行个体化病例审查,放疗计划总体依从性可接受。
  • 不同亚组和照射野安排间协议依从性存在显著差异,IMNI组同侧肺偏差但可接受率为60-80%。
  • 标准切线野和部分宽切线野在两组中依从性最高。

核心结论

  • 个体化病例审查显示KROG-0806试验放疗计划总体依从于协议,但依从性因亚组和照射野安排而异。

研究设计与样本

  • 对KROG-0806Ⅲ期随机试验中747例受试者按内乳淋巴结照射、肿瘤侧别和手术方式分为8个亚组,每组随机抽取15%共102例进行个体化病例审查。

主要发现

  • 放疗计划总体依从性可接受,可接受率为60-80%,但Arm 2(IMNI组)同侧肺存在偏差。
  • 亚组分析显示协议依从性存在显著差异,标准切线和部分宽切线野在两组中依从性最高。
  • 基于内乳淋巴结剂量的估计生存获益在全组、保乳手术组和乳房切除组分别为7.7%、8.4%和7.2%。

临床怎么用

  • 在乳腺癌内乳淋巴结照射的临床试验和临床实践中,应关注不同亚组和照射野安排对协议依从性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE: This study aimed to assess protocol compliance based on an individual case review (ICR) of the Korean Radiation Oncology Group-0806 trial. METHODS AND MATERIALS: For the ICR, 747 participants were divided into eight subgroups based on internal mammary node irradiation (IMNI), tumor laterality, and surgery type. Next, 15% of patients were randomly selected within each subgroup, and corresponding hospitals were subsequently requested to upload information related to radiation therapy (RT) planning. We reviewed the dose distributions of targets and organs at risk to determine protocol compliance. RESULTS: Data of 102 patients were collected. Overall, RT plans were found to be mostly protocol-compliant, with acceptability rates of 60-80% despite deviations in the ipsilateral lung in Arm 2 (IMNI group). However, despite few deviations, a subgroup analysis revealed significant differences in protocol compliance. Among RT techniques, plans using standard and partial wide tangents were most compliant in both Arms. In this ICR, the estimated survival benefits based on IMN doses were 7.7%, 8.4%, and 7.2% for all, breast-conserving surgery, and mastectomy cases, respectively. CONCLUSION: This ICR demonstrated overall protocol compliance, despite significant differences with regard to IMN irradiation and organs at risk according to subgroups and adopted field arrangements.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yoon HI, Yoon J, Chung Y, et al. Individual case review in a phase 3 randomized trial to investigate the role of internal mammary lymph node irradiation for breast cancer: Korean Radiation Oncology Group 08-06 study. Radiother Oncol. 2017. PMID: 28236539. doi:10.1016/j.radonc.2017.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。